Anadamidin rakenteen löysi Israelissa 1992 tsekkiläinen analyytikko ja kemisti Lumir Ondrei Hanus ja amerikkalainen farmakologi William Anthony Devane laboratoriossa, joka sijaitsi hebrealaisessa Yliopistossa Jerusalemissa ja kuului Rafael Mechoulamille.
Anandamide, also known as N-arachidonoylethanolamine or AEA, is an endogenous cannabinoid neurotransmitter. It was isolated and its structure was first described by Czech analytical chemist Lumír Ondřej Hanuš and American molecular pharmacologist William Anthony Devane in the Laboratory of Raphael Mechoulam, at the Hebrew University in Jerusalem, Israel in 1992.
ANANDAMIDI sana on johdettu sanskriitista sanasta ANANDA, mikä tarkoittaa ilo, autuus, ja sanasta AMIDE, amidi.
Molekyyli on syntetisoitunut N-arakidonyyli-fosfatidyyli-etanolaminista useammallakin tavalla.
The name is taken from the Sanskrit word ananda, which means "bliss, delight", and amide.[1][2] It is synthesized from N-arachidonoyl phosphatidylethanolamine by multiple pathways.[3]
Molekyyli hajoaa primääristi FAAH entsyymillä hydrolysoituen , jolloin palautuu arakidonihappoa ja etanolaminia.
It is degraded primarily by the fatty acid amide hydrolase (FAAH) enzyme, which converts anandamide into ethanolamine and arachidonic acid.
Tämän FAAH entsyymin estäjät aiheuttavat, että anandamidin pitoisuudet kohoavat , mitä vaikutusta voidaan terapeuttisesti soveltaa.
As such, inhibitors of FAAH lead to elevated anandamide levels and are being pursued for therapeutic use.[4][5]
Inga kommentarer:
Skicka en kommentar